December 2020, at the annual event of one of the world's largest conferences on breast cancer, the San Antonio Breast Cancer Symposium (SABCS).
This year, MEDSIR participated with the presentation of two studies:
The PARSIFAL study, an international, open-label phase II trial that accrued a total of 486 patients with endocrine-sensitive, estrogen receptor positive (ER[+]) and human epidermal growth factor receptor 2 negative (HER2[-]) metastatic breast cancer (MBC).
The BIOPER study, a multicenter, open-label, non-controlled phase II trial for patients with hormone receptor positive (HR[+]) and human epidermal growth factor receptor 2 negative (HER2[-]) metastatic breast cancer (MBC), who had previously received endocrine therapy (ET) combined with palbociclib (P) and achieved clinical benefit to that treatment before experiencing disease progression.
As a result of the communications that were issued in the United States about these studies, we were contacted by Oncology Tube, a platform of free online videos on oncology dedicated to professionals in the sector.
Last week, Dr. Llombart (researcher of both studies and one of the founders of MEDSIR) had the pleasure of granting these interviews:
Oncology Tube: Will this affect clinicians today?
Dr. Llombart: The data about the toxicity profile of Palbociclib in this study, are very in line with other trials and are confident with what we see in real life. Honestly, I think it is a treatment extremely pleasant for patients and clinicians because toxicities are very low and in general very manageable. This is just a way to say that this is an extraordinary treatment that do not impact on the quality of life of the patient, that do not put in risk a patient because of any underestimated toxicity event.
Oncology Tube: What are your final thoughts on this matter?
Dr. Llombart: I think that out of those findings, the interesting thing is that about one 10th of patients did extremely well so we have identified at least 2-3 patients that are still on going on treatment for more than one and a half year, so meaning that for a small subgroup of patients, probably is consistent with whether we had identified that there is a strong synergism of CDK4/6 Inhibitors and endocrine therapy for more than one line. We need to identify who are those patients; that is our major goal in future studies for the CDK4/6 Inhibitors long term.
We are very happy to have been able to contribute to the breast cancer section of this platform and help to spread and expand cancer research. Of course, the work that Oncology Tube does to collect videos on any type of cancer with oncologists from all over the world is very necessary and fruitful for everyone.
If, like Dr. Llombart, you want to develop an idea and talk about it or, on the contrary, you are a biotech or pharmaceutical company who wants to meet our network of KOLs, do not hesitate to contact us.